<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-461
Date of Submission: 2025-04-16

This report was submitted by a Pharmacist from Martinez, Bates and Young Medical Center concerning patient ANON-PX-1533. The subject is a 66-year-old male with a significant medical history including osteoarthritis, atrial fibrillation, type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 143mg, initiated on 2025-01-24 for Thromboembolism prevention and discontinued on 2025-02-25.

On approximately 2025-02-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Pruritus. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed special and advised loss. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Recognize wish letter owner. Son school open affect.</data>
report_id: ADR-2025-461
report_date: '2025-04-16'
patient_details:
  patient_id: ANON-PX-1533
  gender: Male
  relevant_history:
  - osteoarthritis
  - atrial fibrillation
  - type 2 diabetes
  - migraines
  age_at_reaction: 66
suspected_drugs:
- drug_name: Warfarin
  dosage: 143mg
  route_of_administration: Subcutaneous
  start_date: '2025-01-24'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2025-02-25'
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2025-02-13'
  severity: Severe
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed special and advised loss.
- symptom_name: Pruritus
  onset_date: '2025-02-13'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Martinez, Bates and Young Medical Center
reporter_type: Pharmacist
notes: Recognize wish letter owner. Son school open affect.
